ASND Quote, Financials, Valuation and Earnings

Bicycle Therapeutics PLC has a net margin of -22.12% compared to Ascendis Pharma AS's net margin of -1398.44%. Ascendis Pharma AS's return on equity of -880.05% beat Bicycle Therapeutics PLC's return on equity of -26.21%.

Ascendis Pharma AS has a consensus price target of $211.23, signalling upside risk potential of 38.08%. On the other hand Bicycle Therapeutics PLC has an analysts' consensus of $29.55 which suggests that it could grow by 206.17%. Given that Bicycle Therapeutics PLC has higher upside potential than Ascendis Pharma AS, analysts believe Bicycle Therapeutics PLC is more attractive than Ascendis Pharma AS.

Ascendis Pharma AS has a beta of 0.616, which suggesting that the stock is 38.413% less volatile than S&P 500. In comparison Bicycle Therapeutics PLC has a beta of 1.121, suggesting its more volatile than the S&P 500 by 12.137%.

Ascendis Pharma AS has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bicycle Therapeutics PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ascendis Pharma AS pays -- of its earnings as a dividend. Bicycle Therapeutics PLC pays out -- of its earnings as a dividend.

Ascendis Pharma AS quarterly revenues are $185.4M, which are larger than Bicycle Therapeutics PLC quarterly revenues of $3.7M. Ascendis Pharma AS's net income of -$41M is higher than Bicycle Therapeutics PLC's net income of -$51.9M. Notably, Ascendis Pharma AS's price-to-earnings ratio is -- while Bicycle Therapeutics PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ascendis Pharma AS is 22.60x versus 15.91x for Bicycle Therapeutics PLC. Usually stocks with elevated PS ratios are considered overvalued.

Evaxion Biotech AS has a net margin of -22.12% compared to Ascendis Pharma AS's net margin of -64.14%. Ascendis Pharma AS's return on equity of -880.05% beat Evaxion Biotech AS's return on equity of --.

Ascendis Pharma AS has a consensus price target of $211.23, signalling upside risk potential of 38.08%. On the other hand Evaxion Biotech AS has an analysts' consensus of $13.25 which suggests that it could grow by 644.38%. Given that Evaxion Biotech AS has higher upside potential than Ascendis Pharma AS, analysts believe Evaxion Biotech AS is more attractive than Ascendis Pharma AS.

Ascendis Pharma AS has a beta of 0.616, which suggesting that the stock is 38.413% less volatile than S&P 500. In comparison Evaxion Biotech AS has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Ascendis Pharma AS has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Evaxion Biotech AS offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ascendis Pharma AS pays -- of its earnings as a dividend. Evaxion Biotech AS pays out -- of its earnings as a dividend.

Ascendis Pharma AS quarterly revenues are $185.4M, which are larger than Evaxion Biotech AS quarterly revenues of $3M. Ascendis Pharma AS's net income of -$41M is lower than Evaxion Biotech AS's net income of -$1.9M. Notably, Ascendis Pharma AS's price-to-earnings ratio is -- while Evaxion Biotech AS's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ascendis Pharma AS is 22.60x versus 0.49x for Evaxion Biotech AS. Usually stocks with elevated PS ratios are considered overvalued.

Novo Nordisk AS has a net margin of -22.12% compared to Ascendis Pharma AS's net margin of 32.95%. Ascendis Pharma AS's return on equity of -880.05% beat Novo Nordisk AS's return on equity of 86.85%.

Ascendis Pharma AS has a consensus price target of $211.23, signalling upside risk potential of 38.08%. On the other hand Novo Nordisk AS has an analysts' consensus of $112.90 which suggests that it could grow by 48.19%. Given that Novo Nordisk AS has higher upside potential than Ascendis Pharma AS, analysts believe Novo Nordisk AS is more attractive than Ascendis Pharma AS.

Ascendis Pharma AS has a beta of 0.616, which suggesting that the stock is 38.413% less volatile than S&P 500. In comparison Novo Nordisk AS has a beta of 0.420, suggesting its less volatile than the S&P 500 by 58.038%.

Ascendis Pharma AS has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Novo Nordisk AS offers a yield of 1.88% to investors and pays a quarterly dividend of $0.52 per share. Ascendis Pharma AS pays -- of its earnings as a dividend. Novo Nordisk AS pays out 43.71% of its earnings as a dividend. Novo Nordisk AS's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Ascendis Pharma AS quarterly revenues are $185.4M, which are smaller than Novo Nordisk AS quarterly revenues of $12.2B. Ascendis Pharma AS's net income of -$41M is lower than Novo Nordisk AS's net income of $4B. Notably, Ascendis Pharma AS's price-to-earnings ratio is -- while Novo Nordisk AS's PE ratio is 23.50x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ascendis Pharma AS is 22.60x versus 8.18x for Novo Nordisk AS. Usually stocks with elevated PS ratios are considered overvalued.

Verona Pharma PLC has a net margin of -22.12% compared to Ascendis Pharma AS's net margin of -92.29%. Ascendis Pharma AS's return on equity of -880.05% beat Verona Pharma PLC's return on equity of -88.7%.

Ascendis Pharma AS has a consensus price target of $211.23, signalling upside risk potential of 38.08%. On the other hand Verona Pharma PLC has an analysts' consensus of $81.00 which suggests that it could grow by 31.94%. Given that Ascendis Pharma AS has higher upside potential than Verona Pharma PLC, analysts believe Ascendis Pharma AS is more attractive than Verona Pharma PLC.

Ascendis Pharma AS has a beta of 0.616, which suggesting that the stock is 38.413% less volatile than S&P 500. In comparison Verona Pharma PLC has a beta of 0.392, suggesting its less volatile than the S&P 500 by 60.803%.

Ascendis Pharma AS has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Verona Pharma PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ascendis Pharma AS pays -- of its earnings as a dividend. Verona Pharma PLC pays out -- of its earnings as a dividend.

Ascendis Pharma AS quarterly revenues are $185.4M, which are larger than Verona Pharma PLC quarterly revenues of $36.7M. Ascendis Pharma AS's net income of -$41M is lower than Verona Pharma PLC's net income of -$33.8M. Notably, Ascendis Pharma AS's price-to-earnings ratio is -- while Verona Pharma PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ascendis Pharma AS is 22.60x versus -- for Verona Pharma PLC. Usually stocks with elevated PS ratios are considered overvalued.